Heat Biologics, Inc. (NASDAQ: HTBX) is a clinical-stage biopharmaceutical company developing novel ImPACT therapeutic vaccines to treat a wide range of cancers.  ImPACTTherapy is designed to deliver live, genetically modified, irradiated human cells reprogrammed to “pump out” cancer-associated antigens. The technology is to be used in conjunction with a potent immune adjuvant called “gp96” to educate and activate a cancer patient’s immune system to recognize and kill cancerous cells. Heat expects to enter phase 2 trials with its HS-110 against non-small cell lung cancer and is conducting phase 1/2 clinical trials with its HS-410 against bladder cancer. For more information, visit the company’s website at www.heatbio.com